Form 4: Guardant Health Co-CEO Boosts Stake via RSU Vesting

Guardant Health's Co-CEO, Helmy Eltoukhy, increased his direct beneficial ownership of common stock by 13,209 shares through restricted stock unit vestings and associated tax withholdings.

Summary

• Helmy Eltoukhy, Co-Chief Executive Officer and Director of Guardant Health, Inc. (GH), reported changes in his beneficial ownership of common stock.
• On December 31, 2025, 4,815 shares of common stock vested from a restricted stock unit (RSU) award granted on March 12, 2025.
• Concurrently, 2,441 shares were disposed of at $102.14 per share to cover tax withholding obligations related to this vesting.
• On January 1, 2026, 23,997 shares of common stock vested from an RSU award granted on March 18, 2024.
• Simultaneously, 10,788 shares were disposed of at $102.14 per share for tax withholding purposes related to this vesting.
• Following these transactions, Eltoukhy's direct beneficial ownership of common stock increased by a net of 13,209 shares, from 2,049,517 to 2,062,726 shares.
• He also holds 95,989 unvested restricted stock units from the March 18, 2024 grant.

Sentiment

Score: 7

Explanation: The filing reports routine, pre-scheduled equity compensation transactions for a key executive. The net increase in beneficial ownership is a positive signal of alignment, while tax-related dispositions are standard. No unexpected or negative events are disclosed.

Positives

• Co-CEO Helmy Eltoukhy's beneficial ownership of Guardant Health common stock increased by a net of 13,209 shares, indicating continued alignment with shareholder interests.
• The increase in ownership stems from the vesting of restricted stock units, a common form of equity compensation that incentivizes long-term performance.

Negatives

• A total of 13,229 shares were disposed of to cover tax withholding obligations, which is a standard practice but reduces the immediate direct shareholding.

Future Outlook

The filing details scheduled vesting of restricted stock units, indicating ongoing equity compensation plans for executive management. The remaining 67% of the March 18, 2024 RSU award will continue to vest in equal quarterly installments over the next two years.

Industry Context

This Form 4 filing reflects routine executive compensation practices within the biotechnology and healthcare diagnostics industry, where equity awards like Restricted Stock Units are commonly used to align executive incentives with long-term shareholder value creation. The vesting schedule suggests a standard multi-year retention and performance incentive structure.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a significant component of executive compensation is standard practice across the biotechnology and broader technology sectors, similar to companies like Illumina or Exact Sciences.
• The vesting schedules, such as the three-year vesting period for the March 18, 2024 award, are typical for executive retention and performance incentives, aligning with industry benchmarks for long-term equity grants.
• The disposition of shares to cover tax withholding obligations upon RSU vesting is a common and expected event for equity compensation, consistent with practices observed at peer companies.

Stakeholder Impact

• Shareholders: The net increase in the Co-CEO's direct beneficial ownership aligns management's interests with long-term shareholder value. The routine nature of the transactions provides transparency regarding executive compensation.
• Employees: The filing highlights the company's use of equity compensation, which can be a positive signal for employee retention and motivation if similar programs are available.

Next Steps

• Remaining 67% of the March 18, 2024 RSU award will vest in equal quarterly installments over the next two years.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled equity compensation transactions for a key executive. While the net increase in beneficial ownership is a positive indicator of management alignment, these transactions do not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions are expected and do not alter the underlying investment thesis for Guardant Health.

Keywords

Guardant Health, GH, Helmy Eltoukhy, Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, RSU Vesting, Equity Compensation, Director, Co-CEO